It looks like Merck and Pfizer will be leading the way on new pill for Covid-19 candidates. Pfizer is a double winner on this. Hard for anyone else to compete. RVX should just focus on epigenetics as it is the only real chance they have with their BTD. They need to focus on the necessary financing from where who knows? Maybe Eversana can help maybe but if they don't have about $100 million to invest then why bother. We need new leadership and fast. That would be my focus. Who knows I could be dead wrong.